================================================================
United States
Securities and Exchange Commission
Washington, D.C. 20549
----------------------
FORM 8-K
----------------------
Current Report
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934
July 16, 1998 0-16132
Date of Report Commission File Number
(Date of earliest event reported)
Celgene Corporation
(Exact name of registrant as specified in its charter)
Delaware 22-2711928
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)
7 Powder Horn Drive
Warren, New Jersey 07059
-----------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(732) 271-1001
(Registrant's telephone number, including area code)
================================================================
Item 5. Other Events.
On July 16, 1998, Celgene Corporation (the "Company") received
clearance from the U.S. Food and Drug Administration to market
and sell Thalomid (TM)(Thalidomide)for the treatment of erythema
nodosum leprosum (ENL), a severe and debilitating condition
associated with leprosy.
Item 7. Financial Statements, Unaudited Pro Forma Financial
Information and Exhibits.
(a) Not applicable.
(b) Not applicable
(c) Exhibits
99 Press Release, dated July 16, 1998.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Date: July 21, 1998 CELGENE CORPORATION
By: /s/ John W. Jackson
Name: John W. Jackson
Title: Chairman of the Board and
Chief Executive Officer